<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847443</url>
  </required_header>
  <id_info>
    <org_study_id>RH01705</org_study_id>
    <nct_id>NCT01847443</nct_id>
  </id_info>
  <brief_title>Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations</brief_title>
  <official_title>A Pharmacokinetic Study Comparing Two Nicotine Gum Formulations in a Single Dose Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare pharmacokinetic (PK) profiles and assess
      the bioequivalence between the newly developed nicotine gums (2 mg and 4 mg) and the
      reference nicotine gums (2 mg and 4 mg) in healthy smokers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time 0 to Time 't' [AUC(0-t)] of Nicotine 2 mg Test and Reference Product</measure>
    <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
    <description>AUC(0-t) for 2 mg test was compared with 2 mg reference gum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) of Nicotine 4 mg Test and Reference Product</measure>
    <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
    <description>AUC(0-t) of Nicotine 4 mg test was compared with 4 mg reference gum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Nicotine 2 mg Test and Reference Product</measure>
    <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
    <description>Cmax for 2 mg test was compared with 2 mg reference gum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Nicotine 4 mg Test and Reference Product</measure>
    <time_frame>Blood samples to be collected from baseline to 12 hours post-dose</time_frame>
    <description>Cmax for 4 mg test was compared with 4 mg reference gum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</measure>
    <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
    <description>Tmax for 2 mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Half-life (T1/2) of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</measure>
    <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
    <description>T1/2 of 2 mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Rate Constant (Kel) of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</measure>
    <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
    <description>Kel for 2 mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Concentration-time Curve From Time 0 Extrapolated to ∞ [AUC(0-∞)] of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</measure>
    <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
    <description>AUC(0-∞) for 2mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Test nicotine gum (2 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Nicotine Mint Gum (2 mg) to be chewed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test nicotine gum (4 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Nicotine Mint Gum (4 mg) to be chewed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference nicotine gum (2 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of reference nicotine gum (2 mg) to be chewed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference nicotine gum (4 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of reference nicotine gum (4 mg) to be chewed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine (2 mg)</intervention_name>
    <description>2 mg nicotine gum in two formulations</description>
    <arm_group_label>Reference nicotine gum (2 mg)</arm_group_label>
    <arm_group_label>Test nicotine gum (2 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine (4 mg)</intervention_name>
    <description>4 mg nicotine gum in two formulations</description>
    <arm_group_label>Test nicotine gum (4 mg)</arm_group_label>
    <arm_group_label>Reference nicotine gum (4 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI within the range of 19 to 30 kilograms/meters^2

          -  Current cigarette smokers who have smoked daily for at least a year, and smoke their
             first cigarette within 30 minutes of waking up

        Exclusion Criteria:

          -  Participants who have attempted to quit smoking in the last 12 months, are currently
             attempting to quit smoking or reduce the number of cigarettes they smoke, or are
             intending to quit smoking in the next 3 months, with or without use of smoking
             cessation aids

          -  Treatment with known hepatic enzyme altering agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion - BELFAST</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2013</study_first_submitted>
  <study_first_submitted_qc>May 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2013</study_first_posted>
  <results_first_submitted>March 6, 2014</results_first_submitted>
  <results_first_submitted_qc>March 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 11, 2014</results_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nicotine</keyword>
  <keyword>nicotine replacement therapy</keyword>
  <keyword>nicotine gum</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential participants were recruited at a single site in the UK.</recruitment_details>
      <pre_assignment_details>A total of 160 participants were screened for this study, of which 84 participants were randomized. Seventy seven participants completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>2mg Mint Gum/4mg Ref Gum/4mg Mint Gum/2mg Ref Gum</title>
          <description>Participants randomly received 2mg nicotine mint gum or 4mg reference (ref) nicotine gum or 4mg nicotine mint gum or 2mg ref nicotine gum once daily on Day 1 of treatment period 1. After a 2-7 day washout period, participants were returned to the next treatment period until all four treatment periods were completed.</description>
        </group>
        <group group_id="P2">
          <title>4mg Ref Gum/2mg Ref Gum/2mg Mint Gum/4mg Mint Gum</title>
          <description>Participants randomly received 4mg ref nicotine gum or 2mg ref nicotine gum or 2mg nicotine mint gum or 4mg nicotine mint gum once daily on Day 1 of treatment period 1. After a 2-7 day washout period, participants were returned to the next treatment period until all four treatment periods were completed.</description>
        </group>
        <group group_id="P3">
          <title>2mg Ref Gum/4mg Mint Gum/4mg Ref Gum/2mg Mint Gum</title>
          <description>Participants randomly received 2mg ref nicotine gum or 4mg nicotine mint gum or 4mg ref nicotine gum or 2mg nicotine mint gum once daily on Day 1 of treatment period 1. After a 2-7 day washout period, participants were returned to the next treatment period until all four treatment periods were completed.</description>
        </group>
        <group group_id="P4">
          <title>4mg Mint Gum/2mg Mint Gum/2mg Ref Gum/4mg Ref Gum</title>
          <description>Participants randomly received 4mg nicotine mint gum or 2mg nicotine mint gum or 2mg ref nicotine gum or 4mg ref nicotine gum once daily on Day 1 of treatment period 1. After a 2-7 day washout period, participants were returned to the next treatment period until all four treatment periods were completed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period Before Study Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period Before Study Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period Before Study Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive alcohol test</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time 0 to Time 't' [AUC(0-t)] of Nicotine 2 mg Test and Reference Product</title>
        <description>AUC(0-t) for 2 mg test was compared with 2 mg reference gum</description>
        <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
        <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Nicotine Gum (2 mg)</title>
            <description>A single dose of Nicotine Mint Gum (2 mg) to be chewed.</description>
          </group>
          <group group_id="O2">
            <title>Reference Nicotine Gum (2 mg)</title>
            <description>A single dose of Reference Nicotine Gum (2 mg) to be chewed.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time 0 to Time 't' [AUC(0-t)] of Nicotine 2 mg Test and Reference Product</title>
          <description>AUC(0-t) for 2 mg test was compared with 2 mg reference gum</description>
          <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.49" spread="4.224"/>
                    <measurement group_id="O2" value="10.24" spread="3.768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis stated that there was no difference between the test and reference gums in AUC(0-t)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was to be established between the test and reference treatment if the 90% CI of ratio of geometric means (Test/Reference) was included within the bioequivalence limits of (0.80, 1.25)</non_inferiority_desc>
            <param_type>Ratio of Geometric means</param_type>
            <param_value>1.107</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.070</ci_lower_limit>
            <ci_upper_limit>1.147</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Concentration (Tmax) of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</title>
        <description>Tmax for 2 mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
        <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
        <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Nicotine Gum (2 mg)</title>
            <description>A single dose of Nicotine Mint Gum (2 mg) to be chewed.</description>
          </group>
          <group group_id="O2">
            <title>Reference Nicotine Gum (2 mg)</title>
            <description>A single dose of Reference Nicotine Gum (2 mg) to be chewed.</description>
          </group>
          <group group_id="O3">
            <title>Test Nicotine Gum (4 mg)</title>
            <description>A single dose of Nicotine Mint Gum (4 mg) to be chewed.</description>
          </group>
          <group group_id="O4">
            <title>Reference Nicotine Gum (4 mg)</title>
            <description>A single dose of Reference Nicotine Gum (4 mg) to be chewed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</title>
          <description>Tmax for 2 mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
          <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.5" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.5" upper_limit="1.5"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.5" upper_limit="1.5"/>
                    <measurement group_id="O4" value="0.75" lower_limit="0.2" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Elimination Half-life (T1/2) of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</title>
        <description>T1/2 of 2 mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
        <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
        <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Nicotine Gum (2 mg)</title>
            <description>A single dose of Nicotine Mint Gum (2 mg) to be chewed.</description>
          </group>
          <group group_id="O2">
            <title>Reference Nicotine Gum (2 mg)</title>
            <description>A single dose of Reference Nicotine Gum (2 mg) to be chewed.</description>
          </group>
          <group group_id="O3">
            <title>Test Nicotine Gum (4 mg)</title>
            <description>A single dose of Nicotine Mint Gum (4 mg) to be chewed.</description>
          </group>
          <group group_id="O4">
            <title>Reference Nicotine Gum (4 mg)</title>
            <description>A single dose of Reference Nicotine Gum (4 mg) to be chewed.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Half-life (T1/2) of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</title>
          <description>T1/2 of 2 mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
          <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="1.4" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.03" lower_limit="1.2" upper_limit="4.2"/>
                    <measurement group_id="O3" value="2.01" lower_limit="1.3" upper_limit="4.1"/>
                    <measurement group_id="O4" value="2.02" lower_limit="1.3" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Elimination Rate Constant (Kel) of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</title>
        <description>Kel for 2 mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
        <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
        <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Nicotine Gum (2 mg)</title>
            <description>A single dose of Nicotine Mint Gum (2 mg) to be chewed.</description>
          </group>
          <group group_id="O2">
            <title>Reference Nicotine Gum (2 mg)</title>
            <description>A single dose of Reference Nicotine Gum (2 mg) to be chewed.</description>
          </group>
          <group group_id="O3">
            <title>Test Nicotine Gum (4 mg)</title>
            <description>A single dose of Nicotine Mint Gum (4 mg) to be chewed.</description>
          </group>
          <group group_id="O4">
            <title>Reference Nicotine Gum (4 mg)</title>
            <description>A single dose of Reference Nicotine Gum (4 mg) to be chewed.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Rate Constant (Kel) of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</title>
          <description>Kel for 2 mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
          <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
          <units>1/hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="0.2" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.34" lower_limit="0.2" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.34" lower_limit="0.2" upper_limit="0.5"/>
                    <measurement group_id="O4" value="0.34" lower_limit="0.2" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Concentration-time Curve From Time 0 Extrapolated to ∞ [AUC(0-∞)] of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</title>
        <description>AUC(0-∞) for 2mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
        <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
        <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Nicotine Gum (2 mg)</title>
            <description>A single dose of Nicotine Mint Gum (2 mg) to be chewed.</description>
          </group>
          <group group_id="O2">
            <title>Reference Nicotine Gum (2 mg)</title>
            <description>A single dose of Reference Nicotine Gum (2 mg) to be chewed.</description>
          </group>
          <group group_id="O3">
            <title>Test Nicotine Gum (4 mg)</title>
            <description>A single dose of Nicotine Mint Gum (4 mg) to be chewed.</description>
          </group>
          <group group_id="O4">
            <title>Reference Nicotine Gum (4 mg)</title>
            <description>A single dose of Reference Nicotine Gum (4 mg) to be chewed.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Concentration-time Curve From Time 0 Extrapolated to ∞ [AUC(0-∞)] of Nicotine 2 mg Test and Reference Products, and Nicotine 4 mg Test and Reference Products</title>
          <description>AUC(0-∞) for 2mg test was compared with 2 mg reference gum, and 4 mg test was compared with 4 mg reference gum</description>
          <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.56" spread="4.409"/>
                    <measurement group_id="O2" value="11.20" spread="3.955"/>
                    <measurement group_id="O3" value="24.60" spread="7.845"/>
                    <measurement group_id="O4" value="22.64" spread="7.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-t) of Nicotine 4 mg Test and Reference Product</title>
        <description>AUC(0-t) of Nicotine 4 mg test was compared with 4 mg reference gum</description>
        <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
        <population>Bioequivalence evaluable subjects' population: participants randomized to 1of 4 treatment sequences; took atleast one dose of study medication (both test and ref) in 2 mg dose and/or in 4 mg doses; did not have any AE assimilated to vomiting in first 4h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Nicotine Gum (4 mg)</title>
            <description>A single dose of Nicotine Mint Gum (4 mg) to be chewed.</description>
          </group>
          <group group_id="O2">
            <title>Reference Nicotine Gum (4 mg)</title>
            <description>A single dose of Reference Nicotine Gum (4 mg) to be chewed.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-t) of Nicotine 4 mg Test and Reference Product</title>
          <description>AUC(0-t) of Nicotine 4 mg test was compared with 4 mg reference gum</description>
          <population>Bioequivalence evaluable subjects' population: participants randomized to 1of 4 treatment sequences; took atleast one dose of study medication (both test and ref) in 2 mg dose and/or in 4 mg doses; did not have any AE assimilated to vomiting in first 4h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.44" spread="7.593"/>
                    <measurement group_id="O2" value="21.50" spread="6.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis stated that there was no difference between the test and reference gums in AUC(0-t)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was to be established between the test and reference treatment if the 90% CI of ratio of geometric means (Test/Reference) was included within the bioequivalence limits of (0.80, 1.25)</non_inferiority_desc>
            <param_type>Ratio of Geometric means</param_type>
            <param_value>1.098</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.061</ci_lower_limit>
            <ci_upper_limit>1.137</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) of Nicotine 2 mg Test and Reference Product</title>
        <description>Cmax for 2 mg test was compared with 2 mg reference gum</description>
        <time_frame>Blood samples to be collected from baseline to 12 hours post dose</time_frame>
        <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Nicotine Gum (2 mg)</title>
            <description>A single dose of Nicotine Mint Gum (2 mg) to be chewed.</description>
          </group>
          <group group_id="O2">
            <title>Reference Nicotine Gum (2 mg)</title>
            <description>A single dose of Reference Nicotine Gum (2 mg) to be chewed.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Nicotine 2 mg Test and Reference Product</title>
          <description>Cmax for 2 mg test was compared with 2 mg reference gum</description>
          <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="1.232"/>
                    <measurement group_id="O2" value="3.72" spread="1.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis stated that there was no difference between the test and reference gums in Cmax</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was to be established between the test and reference treatment if the 90% CI of ratio of geometric means (Test/Reference) was included within the bioequivalence limits of (0.80, 1.25)</non_inferiority_desc>
            <param_type>Ratio of Geometric means</param_type>
            <param_value>1.044</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.002</ci_lower_limit>
            <ci_upper_limit>1.089</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Nicotine 4 mg Test and Reference Product</title>
        <description>Cmax for 4 mg test was compared with 4 mg reference gum</description>
        <time_frame>Blood samples to be collected from baseline to 12 hours post-dose</time_frame>
        <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Nicotine Gum (4 mg)</title>
            <description>A single dose of Nicotine Mint Gum (4 mg) to be chewed.</description>
          </group>
          <group group_id="O2">
            <title>Reference Nicotine Gum (4 mg)</title>
            <description>A single dose of Reference Nicotine Gum (4 mg) to be chewed.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Nicotine 4 mg Test and Reference Product</title>
          <description>Cmax for 4 mg test was compared with 4 mg reference gum</description>
          <population>Bioequivalence evaluable subjects' population: participants randomized to 1 of 4 treatment sequences; took atleast one dose of study medication (both test and reference) in 2 mg dose and/or in 4 mg doses; did not have any adverse event assimilated to vomiting in first 4 h post-treatment; and did not have baseline nicotine concentration &gt;5% of Cmax.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.49" spread="1.720"/>
                    <measurement group_id="O2" value="6.98" spread="1.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis stated that there was no difference between the test and reference gums in Cmax</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was to be established between the test and reference treatment if the 90% CI of ratio of geometric means (Test/Reference) was included within the bioequivalence limits of (0.80, 1.25)</non_inferiority_desc>
            <param_type>Ratio of Geometric means</param_type>
            <param_value>1.071</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.028</ci_lower_limit>
            <ci_upper_limit>1.116</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Test Nicotine Gum (2 mg)</title>
          <description>A single dose of Nicotine Mint Gum (2 mg) to be chewed.</description>
        </group>
        <group group_id="E2">
          <title>Reference Nicotine Gum (2 mg)</title>
          <description>A single dose of Reference Nicotine Gum (2 mg) to be chewed.</description>
        </group>
        <group group_id="E3">
          <title>Test Nicotine Gum (4 mg)</title>
          <description>A single dose of Nicotine Mint Gum (4 mg) to be chewed.</description>
        </group>
        <group group_id="E4">
          <title>Reference Nicotine Gum (4 mg)</title>
          <description>A single dose of Reference Nicotine Gum (4 mg) to be chewed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lip blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vessel puncture site anaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

